Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 21

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
$5,283 $8,529 General and administrative1,180 1,419 3,549 4,853 Total operating expenses2,733 3,570 8,832 13,382 Loss from operations(2,733)(3,570)(8,832)(13,382)Other income (expense):Interest income59 48 92 286 Other income, net3 9 185 9 Net loss$(2,671)$(3,513)$(8,555)$(13,087)Loss per share, basic and diluted$(0.06)$(0.25)$(0.33)$(0.95)Weighted average number of shares of common stock, basic and diluted43,042,69113,804,65125,796,75613,742,325

The accompanying notes are an integral part of these condensed financial statements.

2

Table of Contents

INTENSITY THERAPEUTICS, INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

(Unaudited)

Common StockAdditional Paid in CapitalAccumulated DeficitStockholders’ EquitySharesAmount Balances at December 31, 202415,122,873$2 $69,699 $(66,783)$2,918  Issuance of common stock in ATM offering, net of $17 issuance costs 141,996- 328 - 328  Stock-based compensation expense -- 435 - 435  Net loss -- - (3,347)(3,347) Balances at March 31, 202515,264,869$2 $70,462 $(70,130)$334  Stock-based compensation expense -- 644 - 644  Issuance of common stock in public offerings, net of $698 issuance costs 10,809,5831 2,677 - 2,678  Issuance of warrants in public offerings, net of $235 issuance costs-- 1,041 - 1,041  Issuance of common stock in employee stock purchase plan91,971- 24 - 24  Net loss -- - (2,537)(2,537) Balances at June 30, 202526,166,423$3 $74,848 $(